OREXO AB
41Patents
36Active
41Granted
54Portfolio score
Filing activity: Oct 24, 2000 → Dec 18, 2023 · 6 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8470361B2 | Non-abusable pharmaceutical composition comprising opioids | Human Necessities | 29 | Active |
| US7785626B2 | Gastric acid secretion inhibiting composition | Human Necessities | 17 | Expired |
| US8658198B2 | Non-abusable pharmaceutical composition comprising opioids | Human Necessities | 15 | Active |
| US8454996B2 | Pharmaceutical composition for the treatment of acute disorders | Human Necessities | 15 | Active |
| US10653690B1 | Pharmaceutical composition for nasal delivery | Human Necessities | 15 | Active |
| US8815911B2 | Alfentanil composition for the treatment of acute pain | Human Necessities | 10 | Active |
| US8980305B2 | Non-abusable pharmaceutical composition comprising opioids | Human Necessities | 8 | Active |
| US10729687B1 | Pharmaceutical composition for nasal delivery | Human Necessities | 7 | Active |
| US10898480B1 | Pharmaceutical composition for nasal delivery | Human Necessities | 6 | Active |
| US9259421B2 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | Human Necessities | 5 | Active |
| US8940330B2 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | Human Necessities | 5 | Active |
| US9439900B2 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | Human Necessities | 5 | Active |
| US7815940B2 | Gastric acid secretion inhibiting composition | Human Necessities | 4 | Expired |
| US11737980B2 | Pharmaceutical composition for drug delivery | Human Necessities | 2 | Active |
| US10874661B2 | Abuse-resistant pharmaceutical composition for the treatment of opioid dependence | Human Necessities | 2 | Active |
| US11617746B1 | Method of controlling depression in subjects treated for opioid dependence | Human Necessities | 2 | Active |
| US11957647B2 | Pharmaceutical composition comprising adrenaline | Human Necessities | 2 | Active |
| US7910132B2 | Pharmaceutical composition for the treatment of acute disorders | Human Necessities | 2 | Active |
| US11986472B1 | Method of controlling alcohol consumption in subjects treated for opioid dependence | Physics | 1 | Active |
| US8921405B2 | Compounds | Chemistry; Metallurgy | 1 | Active |
| US9345698B2 | Alfentanil composition for the treatment of acute pain | Human Necessities | 1 | Active |
| US8951999B2 | Compounds | Chemistry; Metallurgy | 1 | Active |
| US12303472B2 | Pharmaceutical device for use in intranasal administration | Human Necessities | 1 | Active |
| US12268684B2 | Pharmaceutical composition for nasal delivery | Human Necessities | 1 | Active |
| US8916599B2 | 1H-benz imidazole-5-carboxamides as anti-inflammatory agents | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.